Patents by Inventor Melissa Egbertson

Melissa Egbertson has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10933056
    Abstract: The present invention is directed to pyrazol-4-yl-pyridine compounds which are allosteric modulators of the M4 muscarinic acetylcholine receptor. The present invention is also directed to uses of the compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which M4 muscarinic acetylcholine receptors are involved. The present invention is also directed to compositions comprising these compounds. The present invention is also directed to uses of these compositions in the potential prevention or treatment of such diseases in which M4 muscarinic acetylcholine receptors are involved.
    Type: Grant
    Filed: November 5, 2019
    Date of Patent: March 2, 2021
    Assignees: Merck Sharp & Dohme Corp., MSD R&D (China) Co. Ltd.
    Inventors: John J. Acton, III, Jianming Bao, Melissa Egbertson, Xiaolei Gao, Scott T. Harrison, Sandra L. Knowles, Chunsing Li, Michael Man-Chu Lo, Robert D. Mazzola, Jr., Zhaoyang Meng, Michael T. Rudd, Oleg B. Selyutin, David M. Tellers, Ling Tong, Jenny Miu-Chun Wai
  • Publication number: 20200369677
    Abstract: Pyranoyrazoles and pyrazolopyridines of formula I or formula II are disclosed: These compounds inhibit Coagulation Factor XIIa in the presence of thrombin and other coagulation factors. They are useful to treat autoimmune diseases.
    Type: Application
    Filed: November 28, 2018
    Publication date: November 26, 2020
    Applicant: The Rockefeller University
    Inventors: Manish P. PONDA, Harold SELNICK, Melissa EGBERTSON, Jan L. BRESLOW
  • Publication number: 20200207758
    Abstract: The present invention is directed to pyrazol-4-yl-pyridine compounds which are allosteric modulators of the M4 muscarinic acetylcholine receptor. The present invention is also directed to uses of the compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which M4 muscarinic acetylcholine receptors are involved. The present invention is also directed to compositions comprising these compounds. The present invention is also directed to uses of these compositions in the potential prevention or treatment of such diseases in which M4 muscarinic acetylcholine receptors are involved.
    Type: Application
    Filed: June 22, 2018
    Publication date: July 2, 2020
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: John J. ACTON, III, Jianming BAO, Qiaolin DENG, Melissa EGBERTSON, Ronald FERGUSON, II, Xiaolei GAO, Scott Timothy HARRISON, Sandra L. KNOWLES, Chunsing LI, Michael Man-Chu LO, Robert D. MAZZOLA, Jr., Zhaoyang MENG, Meng NA, Michael T. RUDD, Oleg SELYUTIN, David M. TELLERS, Ling TONG, Fengqi ZHANG
  • Publication number: 20200069671
    Abstract: The present invention is directed to pyrazol-4-yl-pyridine compounds which are allosteric modulators of the M4 muscarinic acetylcholine receptor. The present invention is also directed to uses of the compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which M4 muscarinic acetylcholine receptors are involved. The present invention is also directed to compositions comprising these compounds. The present invention is also directed to uses of these compositions in the potential prevention or treatment of such diseases in which M4 muscarinic acetylcholine receptors are involved.
    Type: Application
    Filed: November 5, 2019
    Publication date: March 5, 2020
    Applicants: Merck Sharp & Dohme Corp., MSD R & D (China) Co., Ltd.
    Inventors: John J. Acton, III, Jianming Bao, Melissa Egbertson, Xiaolei Gao, Scott T. Harrison, Sandra L. Knowles, Chunsing Li, Michael Man-Chu Lo, Robert D. Mazzola, JR., Zhaoyang Meng, Michael T. Rudd, Oleg B. Selyutin, David M. Tellers, Ling Tong, Jenny Miu-Chun Wai
  • Patent number: 10538512
    Abstract: 2-Acylindazole compounds of formula I or formula II are disclosed: These compounds inhibit Coagulation Factor XIIa. They are useful to treat autoimmune diseases.
    Type: Grant
    Filed: May 22, 2017
    Date of Patent: January 21, 2020
    Assignee: The Rockefeller University
    Inventors: Manish P. Ponda, Jan L. Breslow, Harold Selnick, Melissa Egbertson
  • Publication number: 20190202811
    Abstract: 2-Acylindazole compounds of formula I or formula II are disclosed: These compounds inhibit Coagulation Factor XIIa. They are useful to treat autoimmune diseases.
    Type: Application
    Filed: May 22, 2017
    Publication date: July 4, 2019
    Applicant: The Rockefeller University
    Inventors: Manish P. PONDA, Jan L. BRESLOW, Harold SELNICK, Melissa EGBERTSON
  • Publication number: 20190000824
    Abstract: The present invention is directed to pyrazol-4-yl-pyridine compounds which are allosteric modulators of the M4 muscarinic acetylcholine receptor. The present invention is also directed to uses of the compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which M4 muscarinic acetylcholine 5 receptors are involved. The present invention is also directed to compositions comprising these compounds. The present invention is also directed to uses of these compositions in the potential prevention or treatment of such diseases in which M4 muscarinic acetylcholine receptors are involved.
    Type: Application
    Filed: December 19, 2016
    Publication date: January 3, 2019
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: John J. Acton, III, Jianming Bao, Melissa Egbertson, Xiaolei Gao, Scott T. Harrison, Sandra L. Knowles, Chunsing Li, Michael Man-Chu Lo, Robert D. Mazzola, Jr., Zhaoyang Meng, Michael T. Rudd, Oleg B. Selyutin, David M. Tellers, Ling Tong, Jenny Miu-Chun Wai
  • Patent number: 9815796
    Abstract: Disclosed are pyrimidine carboxamide compounds of formula (I) which are useful as therapeutic agents for the treatment of central nervous system disorders associated with phosphodiesterase 2 (PDE2), pharmaceutical compositions and uses thereof.
    Type: Grant
    Filed: December 17, 2014
    Date of Patent: November 14, 2017
    Assignees: Merck Sharp & Dohme Corp., MSD R & D (China) Co. LTD.
    Inventors: Dong Ming Shen, Melissa Egbertson, Richard Berger, XiaoXia Qian, Yimin Qian, Bart Harper, Meng Yang, Zack Zhiqiang Guo, Vanessa L. Rada, Deping Wang, Timothy A. Cernak, Christopher Sinz, Ming Wang, Jonathan E. Wilson, Shimin Xu
  • Patent number: 9586968
    Abstract: Disclosed are compounds of Formula A-a, or a salt thereof: Where “B1” and “R1” through “R5” are as defined herein, which compounds have properties for blocking Nav 1.7 ion channels found in peripheral and sympathetic neurons. Also described are pharmaceutical formulations comprising the compounds of Formula A-a or their salts, and methods of treating neuropathic pain disorders using the same.
    Type: Grant
    Filed: November 24, 2014
    Date of Patent: March 7, 2017
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Mark E. Layton, Anthony J. Roecker, Melissa Egbertson, Kristen L. G. Jones, Dansu Li, Xiu Wang, Xuanjia Peng
  • Publication number: 20170015633
    Abstract: Disclosed are pyrimidine carboxamide compounds of formula (I) which are useful as therapeutic agents for the treatment of central nervous system disorders associated with phosphodiesterase 2 (PDE2), pharmaceutical compositions and uses thereof.
    Type: Application
    Filed: December 17, 2014
    Publication date: January 19, 2017
    Applicants: Merck Sharp & Dohme Corp., MSD R & D (China) Co. LTD.
    Inventors: Dong Ming Shen, Melissa Egbertson, Richard Berger, XiaoXia Qian, Yimin Qian, Bart Harper, Meng Yang, Zack Zhi Qiang Guo, Vanessa L. Rada, Deping Wang, Timothy A. Cernak, Christopher Sinz, Ming Wang, Jonathan E. Wilson, Shimin Xu
  • Publication number: 20170002008
    Abstract: Disclosed are compounds of Formula A-a, or a salt thereof: Where “B1” and “R1” through “R5” are as defined herein, which compounds have properties for blocking Nav 1.7 ion channels found in peripheral and sympathetic neurons. Also described are pharmaceutical formulations comprising the compounds of Formula A-a or their salts, and methods of treating neuropathic pain disorders using the same.
    Type: Application
    Filed: November 24, 2014
    Publication date: January 5, 2017
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Mark E. Layton, Anthony J. Roecker, Melissa Egbertson, Kristen L. G. Jones, Dansu Li, Xiu Wang, Xuanjia Peng
  • Patent number: 9181261
    Abstract: The present invention is directed to benzyl urea compounds, which are tropomyosin-related kinase (Trk) family protein kinase inhibitors, and hence may be useful in the treatment of pain, inflammation, cancer, restenosis, atherosclerosis, psoriasis, thrombosis, a disease, disorder, injury, or malfunction relating to dysmyelination or demyelination or a disease or disorder associated with abnormal activities of nerve growth factor (NGF) receptor Trk-A, Trk-B and/or Trk-C.
    Type: Grant
    Filed: May 17, 2013
    Date of Patent: November 10, 2015
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Shawn J. Stachel, Melissa Egbertson, Edward Brnardic, Kristen G. Jones, John M. Sanders, Darrell Henze
  • Publication number: 20150141428
    Abstract: The present invention is directed to benzyl urea compounds, which are tropomyosin-related kinase (Trk) family protein kinase inhibitors, and hence may be useful in the treatment of pain, inflammation, cancer, restenosis, atherosclerosis, psoriasis, thrombosis, a disease, disorder, injury, or malfunction relating to dysmyelination or demyelination or a disease or disorder associated with abnormal activities of nerve growth factor (NGF) receptor Trk-A, Trk-B and/or Trk-C.
    Type: Application
    Filed: May 17, 2013
    Publication date: May 21, 2015
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Shawn J. Stachel, Melissa Egbertson, Edward Brnardic, Kristen G. Jones, John M. Sanders, Darrell Henze
  • Patent number: 8829196
    Abstract: The present invention relates to compositions and methods that modulate at least one TRP family member. Specifically, the present invention relates to novel TRPA1 antagonists and their use in the treatment of pain such as chronic inflammatory and neuropathic pain. Compounds that can modulate one or more TRPA1 functions are useful in many aspects including, but not limited to, maintaining calcium homeostasis; maintaining sodium homeostasis; modulating intracellular calcium levels; modulating membrane polarization (membrane potential); modulating cation levels; and/or treating or preventing diseases, disorders, or conditions associated with calcium homeostasis, sodium homeostasis, calcium or sodium dyshomeostasis, or membrane polarization/hyperpolarization (including hypo and hyperexcitability), and/or treating or preventing diseases, disorders, or conditions associated with regulation or misregulation of TRPA1 expression or function.
    Type: Grant
    Filed: September 28, 2010
    Date of Patent: September 9, 2014
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Mark T. Bilodeau, Melissa Egbertson, Ahren Green, John C. Hartnett, Yiwei Li
  • Patent number: 8680116
    Abstract: The present invention is directed to quinolinone compounds which are useful as therapeutic agents for the treatment of central nervous system disorders associated with phosphodiesterase 2 (PDE2). The present invention also relates to the use of such compounds for treating neurological and psychiatric disorders, such as schizophrenia, psychosis or Huntington's disease, and those associated with striatal hypofunction or basal ganglia dysfunction.
    Type: Grant
    Filed: July 19, 2010
    Date of Patent: March 25, 2014
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Pablo DeLeon, Melissa Egbertson, Ivory D. Hills, Adam Wayne Johnson, Michelle Machacek
  • Publication number: 20130178468
    Abstract: Tricyclic compounds of Formula I are inhibitors of HIV integrase and inhibitors of HIV replication: wherein bond a, ring A, R1, R2 and R3 are defined herein. The compounds are useful for the prophylaxis or treatment of infection by HIV and the prophylaxis, treatment, or delay in the onset of AIDS. The compounds are employed against HIV infection and AIDS as compounds per se or in the form of pharmaceutically acceptable salts. The compounds and their salts can be employed as ingredients in pharmaceutical compositions, optionally in combination with other antivirals, immunomodulators, antibiotics or vaccines.
    Type: Application
    Filed: September 7, 2012
    Publication date: July 11, 2013
    Inventors: Joseph P. Vacca, John S. Wai, Linda S. Payne, Richard C. A. Isaccs, Wei Han, Melissa Egbertson, Richard Pracitto
  • Publication number: 20120196894
    Abstract: The present invention relates to compositions and methods that modulate at least one TRP family member. Specifically, the present invention relates to novel TRPA1 antagonists and their use in the treatment of pain such as chronic inflammatory and neuropathic pain. Compounds that can modulate one or more TRPA1 functions are useful in many aspects including, but not limited to, maintaining calcium homeostasis; maintaining sodium homeostasis; modulating intracellular calcium levels; modulating membrane polarization (membrane potential); modulating cation levels; and/or treating or preventing diseases, disorders, or conditions associated with calcium homeostasis, sodium homeostasis, calcium or sodium dyshomeostasis, or membrane polarization/hyperpolarization (including hypo and hyperexcitability), and/or treating or preventing diseases, disorders, or conditions associated with regulation or misregulation of TRPA1 expression or function.
    Type: Application
    Filed: September 28, 2010
    Publication date: August 2, 2012
    Inventors: Mark T. Bilodeau, Melissa Egbertson, Ahren Green, John C. Hartnett, Yiwei Li
  • Publication number: 20120115885
    Abstract: The present invention is directed to quinolinone compounds which are useful as therapeutic agents for the treatment of central nervous system disorders associated with phosphodiesterase 2 (PDE2). The present invention also relates to the use of such compounds for treating neurological and psychiatric disorders, such as schizophrenia, psychosis or Huntington's disease, and those associated with striatal hypofunction or basal ganglia dysfunction.
    Type: Application
    Filed: July 19, 2010
    Publication date: May 10, 2012
    Inventors: Pablo De Leon, Melissa Egbertson, Ivory D. Hills, Adam Wayne Johnson, Michelle Machacek
  • Patent number: 7598264
    Abstract: Hydroxy (tetra- or hexa-)hydronaphthyridine dione compounds of Formula I are inhibitors of HIV integrase and inhibitors of HIV replication: (I) wherein a, R1?, R2?, R3?, R4? and R5? are defined herein. The compounds are useful in the prevention and treatment of infection by HIV and in the prevention, delay in the onset, and treatment of AIDS. The compounds are employed against HIV infection and AIDS as compounds per se or in the form of pharmaceutically acceptable salts. The compounds and their salts can be employed as ingredients in pharmaceutical compositions, optionally in combination with other antivirals, immunomodulators, antibiotics or vaccines.
    Type: Grant
    Filed: March 9, 2005
    Date of Patent: October 6, 2009
    Assignee: Merck & Co., Inc.
    Inventors: Wei Han, Melissa Egbertson, John S. Wai, Linghang Zhuang, Rowena D. Ruzek, Debra S. Perlow, Mark Cameron, Bruce S. Foster, Ulf H. Dolling, R. Scott Hoerrner, Philip J. Pye, Remy Angelaud, Danny E. Mancheno, David Askin
  • Publication number: 20090054399
    Abstract: Tricyclic compounds of Formula (I) are inhibitors of HIV integrase and inhibitors of HIV replication: wherein bond a, ring A, R1, R2 and R3 are defined herein. The compounds are useful for the prophylaxis or treatment of infection by HIV and the prophylaxis, treatment, or delay in the onset of AIDS. The compounds are employed against HIV infection and AIDS as compounds per se or in the form of pharmaceutically acceptable salts. The compounds and their salts can be employed as ingredients in pharmaceutical compositions, optionally in combination with other antivirals, immunomodulators, antibiotics or vaccines.
    Type: Application
    Filed: May 5, 2006
    Publication date: February 26, 2009
    Inventors: Joseph P. Vacca, John S. Wai, Linda S. Payne, Richard C.A. Isaacs, Wei Han, Melissa Egbertson, Richard Pracitto